U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H16N2O6S3
Molecular Weight 404.482
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SULFOXONE

SMILES

OS(=O)CNC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(NCS(O)=O)C=C2

InChI

InChIKey=NEDPPCHNEOMTJV-UHFFFAOYSA-N
InChI=1S/C14H16N2O6S3/c17-23(18)9-15-11-1-5-13(6-2-11)25(21,22)14-7-3-12(4-8-14)16-10-24(19)20/h1-8,15-16H,9-10H2,(H,17,18)(H,19,20)

HIDE SMILES / InChI

Molecular Formula C14H16N2O6S3
Molecular Weight 404.482
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Sulfoxone is a water-soluble sulfone and is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. Sulfoxone under the brand name Diasone was used as an antileprosy drug, for treatment of dermatitis herpetiformis, and to treat pulmonary tuberculosis. Presently, usage of diasone has been discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DIASONE SODIUM

Approved Use

Unknown

Launch Date

5.11401591E11
Primary
DIASONE SODIUM

Approved Use

Unknown

Launch Date

5.11401591E11
Primary
DIASONE SODIUM

Approved Use

Unknown

Launch Date

5.11401591E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
600 ng/mL
330 mg single, oral
dose: 330 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DAPSONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
Other AEs: Nausea, Weakness...
Other AEs:
Nausea
Weakness
Sources:
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
Other AEs: Malaise...
1.2 g 1 times / day multiple, oral
Dose: 1.2 g, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 g, 1 times / day
Sources:
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
Disc. AE: Hemolytic anemia, Methemoglobinemia...
AEs leading to
discontinuation/dose reduction:
Hemolytic anemia
Methemoglobinemia
Sources:
0.3 g 3 times / day multiple, oral
Dose: 0.3 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.3 g, 3 times / day
Sources:
unhealthy, 52 years
n = 1
Health Status: unhealthy
Condition: leprosy
Age Group: 52 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Erythema facial, Erythema...
AEs leading to
discontinuation/dose reduction:
Erythema facial
Erythema
Furunculosis
Sources:
AEs

AEs

AESignificanceDosePopulation
Nausea
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
Weakness
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
Malaise
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
Hemolytic anemia Disc. AE
1.2 g 1 times / day multiple, oral
Dose: 1.2 g, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 g, 1 times / day
Sources:
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
Methemoglobinemia Disc. AE
1.2 g 1 times / day multiple, oral
Dose: 1.2 g, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 g, 1 times / day
Sources:
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
Erythema facial Disc. AE
0.3 g 3 times / day multiple, oral
Dose: 0.3 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.3 g, 3 times / day
Sources:
unhealthy, 52 years
n = 1
Health Status: unhealthy
Condition: leprosy
Age Group: 52 years
Sex: M
Population Size: 1
Sources:
Erythema Disc. AE
0.3 g 3 times / day multiple, oral
Dose: 0.3 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.3 g, 3 times / day
Sources:
unhealthy, 52 years
n = 1
Health Status: unhealthy
Condition: leprosy
Age Group: 52 years
Sex: M
Population Size: 1
Sources:
Furunculosis Disc. AE
0.3 g 3 times / day multiple, oral
Dose: 0.3 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.3 g, 3 times / day
Sources:
unhealthy, 52 years
n = 1
Health Status: unhealthy
Condition: leprosy
Age Group: 52 years
Sex: M
Population Size: 1
Sources:
PubMed

PubMed

TitleDatePubMed
Impact of glycemic control on the incidence of acute kidney injury in critically ill patients: a comparison of two strategies using the RIFLE criteria.
2010 Jun

Sample Use Guides

Unknown
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:18:27 UTC 2023
Edited
by admin
on Fri Dec 15 16:18:27 UTC 2023
Record UNII
0G3C18OH4D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SULFOXONE
Common Name English
METHANESULFINIC ACID, (SULFONYLBIS(4,1-PHENYLENEIMINO))BIS-
Common Name English
Aldesulfone [WHO-DD]
Common Name English
ALDESULFONE
WHO-DD  
Common Name English
(SULFONYLBIS(4,1-PHENYLENEIMINO))DIMETHANESULFINIC ACID
Systematic Name English
ALDESULPHONE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29739
Created by admin on Fri Dec 15 16:18:27 UTC 2023 , Edited by admin on Fri Dec 15 16:18:27 UTC 2023
Code System Code Type Description
WIKIPEDIA
Sulfoxone
Created by admin on Fri Dec 15 16:18:27 UTC 2023 , Edited by admin on Fri Dec 15 16:18:27 UTC 2023
PRIMARY
NCI_THESAURUS
C72856
Created by admin on Fri Dec 15 16:18:27 UTC 2023 , Edited by admin on Fri Dec 15 16:18:27 UTC 2023
PRIMARY
SMS_ID
100000077970
Created by admin on Fri Dec 15 16:18:27 UTC 2023 , Edited by admin on Fri Dec 15 16:18:27 UTC 2023
PRIMARY
EVMPD
SUB12767MIG
Created by admin on Fri Dec 15 16:18:27 UTC 2023 , Edited by admin on Fri Dec 15 16:18:27 UTC 2023
PRIMARY
FDA UNII
0G3C18OH4D
Created by admin on Fri Dec 15 16:18:27 UTC 2023 , Edited by admin on Fri Dec 15 16:18:27 UTC 2023
PRIMARY
MESH
C036115
Created by admin on Fri Dec 15 16:18:27 UTC 2023 , Edited by admin on Fri Dec 15 16:18:27 UTC 2023
PRIMARY
DRUG CENTRAL
2533
Created by admin on Fri Dec 15 16:18:27 UTC 2023 , Edited by admin on Fri Dec 15 16:18:27 UTC 2023
PRIMARY
CAS
144-76-3
Created by admin on Fri Dec 15 16:18:27 UTC 2023 , Edited by admin on Fri Dec 15 16:18:27 UTC 2023
PRIMARY
DRUG BANK
DB01145
Created by admin on Fri Dec 15 16:18:27 UTC 2023 , Edited by admin on Fri Dec 15 16:18:27 UTC 2023
PRIMARY
EPA CompTox
DTXSID80162594
Created by admin on Fri Dec 15 16:18:27 UTC 2023 , Edited by admin on Fri Dec 15 16:18:27 UTC 2023
PRIMARY
PUBCHEM
5351
Created by admin on Fri Dec 15 16:18:27 UTC 2023 , Edited by admin on Fri Dec 15 16:18:27 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY